Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by BearDownAZ


T.RVX

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Question on FA timing? Bear?

G1945V, It helps to think about BETonMACE not only in terms of when first...

September 2, 2017

T.RVX

RE:RE:RE:RE:RE:RE:RE:RE:RE:Question on FA timing? Bear?

G1945V, I've posted on this subject exhaustively on Agoracom in the "...

September 2, 2017

T.RVX

RE:RE:RE:RE:RE:RE:RE:Question on FA timing? Bear?

G1945V wrote: "Bear what I am saying I guess is..." what if" ....

September 1, 2017

T.RVX

RE:RE:RE:RE:RE:Question on FA timing? Bear?

G1945V wrote: "who's to say that that MACE events are actually...

September 1, 2017

T.RVX

RE:RE:RE:Question on FA timing? Bear?

I'm pretty sure it's 1:1 for statin type and 1:1 for placebo vs...

August 30, 2017

T.RVX

RE:Question on FA timing? Bear?

Trial is randomized 1:1 as presented on all BETonMACE trial design slides the...

August 30, 2017

T.RVX

RE:RE:RE:RE:Perhaps Bear can connect the dots on CANTOS-Canakinumab

The 14 to 15 percent IS the RRR.

August 30, 2017

V.BTI.H

RE:RE:RE:RE:RE:RE:Information circular...

There is probably a down payment to the chosen contractor, but full payment...

August 30, 2017

T.RVX

RE:RE:Perhaps Bear can connect the dots on CANTOS-Canakinumab

In CANTOS, they met their primary endpoint (3-point MACE) with statistical...

August 29, 2017

ESPR

@EsperionInc narration of ESC 2017 presentation

A very nice narration on Twitter by @EsperionInc the of Dr. Stephen...

August 28, 2017

T.RVX

RE:RE:Sarah- Confirmation

And even if that statement is loosely interpreted as before markets open on...

August 27, 2017

T.RVX

RE:Loan/FA

Tiger86, I sure hope you're right. The symposium at ESC will wrap...

August 25, 2017

V.BTI.H

RE:Trastuzumab

"In conclusion, our data provide a rationale for the clinical evaluation...

August 11, 2017

V.BTI.H

RE:Trastuzumab distribution

"This study is one of the first studies to measure antibody movement...

August 11, 2017

V.BTI.H

RE:DDF Summit: Drug Delivery & Formulation, August 28-29, 2017

Per Graeme, biOasis is no longer attending and Reinhard Gabathuler is not...

August 10, 2017

V.BTI.H

RE:RE:DDF Summit: Drug Delivery & Formulation, August 28-29, 2017

BigDolphin wrote: "You still own this BD?" Yes. Doubled my...

August 10, 2017

V.BTI.H

DDF Summit: Drug Delivery & Formulation, August 28-29, 2017

DDF Summit: Drug Delivery & Formulation, August 28-29, 2017 http://www...

August 9, 2017

ESPR

RE:A great day for Esperion

A couple nice Seeking Alpha articles on ESPR from today: Esperion's...

August 9, 2017

ESPR

A great day for Esperion

Shares up 25% today as of right now, and as John Carroll pointed out in his...

August 8, 2017

V.BTI.H

RE:biOasis (BTI:TSXV) Corporate Shareholder Email Distribution

Apparently Graeme and Catherine think those over at Agoracom need a little...

August 5, 2017